New triple therapy aims to wipe out aggressive breast cancer before surgery
Disease control
Recruiting now
This study tests whether adding a drug called axatilimab (which targets immune cells) and radiation to standard immunotherapy (pembrolizumab) can completely eliminate triple-negative breast cancer before surgery. About 35 women with high-risk, early-stage disease will receive thi…
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated May 03, 2026 13:47 UTC